Applied Health Economics and Health Policy

Papers
(The H4-Index of Applied Health Economics and Health Policy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data91
Willingness to Pay for a COVID-19 Vaccine89
The Role of Mental Health on Workplace Productivity: A Critical Review of the Literature41
Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data33
Analysing the Efficiency of Health Systems: A Systematic Review of the Literature32
Health Financing in Sub-Saharan Africa: From Analytical Frameworks to Empirical Evaluation31
Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward30
How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany29
The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis28
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland28
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options27
Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America25
Population Norms for SF-6Dv2 and EQ-5D-5L in China22
Costs of Illness of Spinal Muscular Atrophy: A Systematic Review21
The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review21
How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/1320
The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review20
Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme20
COVID-19 Vaccine Demand and Financial Incentives20
Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis19
‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions19
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives19
0.12621808052063